A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naive Pre-pubertal Children With Growth Hormone Deficiency naive Pre-pubertal Children With Growth Hormone Deficiency

Trial Profile

A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naive Pre-pubertal Children With Growth Hormone Deficiency naive Pre-pubertal Children With Growth Hormone Deficiency

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Somapacitan (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2017 Planned End Date changed from 2 Oct 2020 to 31 Aug 2020.
    • 03 May 2017 Planned End Date changed from 17 Apr 2020 to 2 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top